Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cilomilast.

E Neil Schachter1

  • 1Division of Pulmonary Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. neil.schachter@mssm.edu

Drugs of Today (Barcelona, Spain : 1998)
|May 17, 2006
PubMed
Summary
This summary is machine-generated.

Cilomilast, a selective phosphodiesterase-4 inhibitor, shows promise in treating chronic obstructive pulmonary disease by reducing key inflammatory cells. This second-generation drug offers therapeutic benefits with a potentially improved side-effect profile compared to older agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of monoclonal antibodies and related agents in the treatment of respiratory disease.

Drugs of today (Barcelona, Spain : 1998)·2009
Same author

Use of inhaled epoprostenol in transition to extubation in a patient after implantation of a ventricular assist device.

Journal of cardiothoracic and vascular anesthesia·2009
Same author

Gender and respiratory findings in workers occupationally exposed to organic aerosols: a meta analysis of 12 cross-sectional studies.

Environmental health : a global access science source·2009
Same author

Respiratory function in pesticide workers.

Journal of occupational and environmental medicine·2008
Same author

Pharmacologic effects of grain weevil extract on isolated guinea pig tracheal smooth muscle.

Lung·2008
Same author

Targeted therapies for the prevention of lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2008
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pharmacology
  • Pulmonology
  • Immunology

Background:

  • Cyclic nucleotides are crucial intracellular second messengers, with phosphodiesterases (PDEs) regulating their activity.
  • Methylxanthines were early PDE inhibitors used in respiratory medicine, but side effects limited their use.
  • The discovery of PDE isoforms has renewed interest in developing selective PDE inhibitors for therapeutic applications.

Purpose of the Study:

  • To evaluate cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor, as a potential treatment for chronic obstructive pulmonary disease (COPD).
  • To assess the anti-inflammatory effects of cilomilast by measuring its impact on macrophages and CD8+ lymphocytes in COPD patients.
  • To characterize the pharmacokinetic profile and safety of cilomilast in the context of COPD treatment.

Main Methods:

Related Experiment Videos

  • Cilomilast, a second-generation selective PDE4 inhibitor, was administered orally to patients with COPD.
  • The study assessed the reduction of inflammatory cells, specifically macrophages and CD8+ lymphocytes, in COPD patients treated with cilomilast.
  • Pharmacokinetic parameters including absorption, metabolism, and elimination half-life were determined.
  • Clinical trials were conducted to evaluate the efficacy and safety profile of cilomilast.

Main Results:

  • Cilomilast demonstrated a reduction in macrophages and CD8+ lymphocytes, key inflammatory cells in COPD.
  • The drug is completely absorbed orally with negligible first-pass metabolism and a terminal elimination half-life of approximately 6.5 hours.
  • A twice-daily dose of 15 mg was found to be clinically effective.
  • Preliminary clinical studies indicate a favorable clinical effect in COPD patients, with nausea being the principal adverse reaction.

Conclusions:

  • Cilomilast is a systemically available, selective PDE4 inhibitor with potential therapeutic activity in COPD.
  • It effectively reduces inflammatory cells implicated in the pathogenesis of COPD.
  • Cilomilast exhibits favorable pharmacokinetics and is generally well-tolerated, with a potentially improved side-effect profile compared to older PDE inhibitors.